# Hemodynamic-GUIDEd Management of Heart Failure

> **NCT03387813** · NA · COMPLETED · sponsor: **Abbott Medical Devices** · enrollment: 2358 (actual)

## Conditions studied

- Heart Failure
- Heart Failure, Systolic
- Heart Failure, Diastolic
- Heart Failure NYHA Class II
- Heart Failure NYHA Class III
- Heart Failure NYHA Class IV
- Heart Failure，Congestive
- Heart Failure With Reduced Ejection Fraction
- Heart Failure With Normal Ejection Fraction
- Heart Failure; With Decompensation

## Interventions

- **DEVICE:** CardioMEMS™ HF System

## Key facts

- **NCT ID:** NCT03387813
- **Lead sponsor:** Abbott Medical Devices
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-15
- **Primary completion:** 2023-05-17
- **Final completion:** 2023-05-17
- **Target enrollment:** 2358 (ACTUAL)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03387813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03387813, "Hemodynamic-GUIDEd Management of Heart Failure". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT03387813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*